commerci drive strength solid order guid gener better
post reason strong end strength commerci greater anticip benefit fx drove
revenu beat continu trend decent perform albeit core deceler sequenti ih remain
notabl challeng book front solid outcom show continu sign acceler
bode well beyond solut turn margin appear notabl robust slightli higher opex still
translat strong margin outcom reason ebitda beat move line interest came littl
hot eat away penni ep like off-set higher tax rate modestli lower share count thu
ep beat appear primarili oper natur pleas investor turn initi guidanc thing
get complex given chang commerci appear better line ih forecast
ebitda ep result appear notabl better drive rel strength share today would note
compani also up buy-back provid firepow share earli all-in complex solid
result expect share today pend major volatil market
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
expect in-lin revenu slight ep initi guid slightli consist w/ ad
histor perform last yr ep qs move flattish
fy guidanc provid old report format new
posit ttm adjust net order bn vs evr bn
neutral backlog burn rate decreas q-o-q
posit commerci solut core growth ex fx vs evr
neutral core ex fx vs evr
neg core growth declin ex fx vs evr
posit us corpor tax reform reduc adjust book tax rate
updat detail demand impact nextgen oce among current busi momentum
detail assumpt behind puts/tak ebitda ep guidanc inclus invest vs omx
color book win outlook potenti underli acceler
thought medium term margin path potenti impact benefit shift cro price model
valuat methodolog valuat methodolog base mix discount cash flow analysi rel valuat
risk disrupt revenu growth inabl replac unforeseen cancel new busi moder
biotech demand due capit market volatil dri invest paus rfp activ follow larg round
pharma industri consolid
articl articl
time dissemin februari et
analyst ross muken luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
